Spectrum Pharmaceuticals (NASDAQ:SPPI) recently announced approval from the Food and Drug Administration for a new manufacturing facility for its top-selling drug, Fusilev. While the news is a positive from a risk-management perspective, it does little to address the large cloud looming over the stock. Fusilev's success is largely attributable to supply shortages of a generic drug Leucovorin, used as part of typical chemotherapy treatments for colorectal cancer. As Brenton Flynn explains in the following video, as long as those supply shortages remain, investors can't truly know whether Fusilev will stand on its own or fall to the competition.
The Fusilev overhang has similarities to Questcor Pharmaceuticals' (Nasdaq:QCOR) recent dilemma. Insurance reimbursement and government investigation concerns have caused considerable investor doubts around the stock. While both Spectrum and Questcor appear cheap using traditional valuation metrics, these risks will are likely to continue.
Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Biotech Stocks to Be Thankful for This Year
If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum's preliminary lung cancer data sparked a noteworthy rally in its shares last month.
3 Healthcare Stocks That Soared This Week: Are They Buys?
Can the sizzling momentum continue for TransEnterix, uniQure, and Spectrum Pharmaceuticals?